Eli Lilly and Company (NYSE:LLY) Shares Sold by Chilton Capital Management LLC

Chilton Capital Management LLC lowered its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 1.6% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 69,431 shares of the company's stock after selling 1,143 shares during the quarter. Eli Lilly and Company accounts for 2.5% of Chilton Capital Management LLC's holdings, making the stock its 8th biggest holding. Chilton Capital Management LLC's holdings in Eli Lilly and Company were worth $57,344,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. Tradewinds LLC. lifted its stake in shares of Eli Lilly and Company by 3.7% during the 1st quarter. Tradewinds LLC. now owns 6,002 shares of the company's stock worth $4,957,000 after purchasing an additional 215 shares during the last quarter. Cloud Capital Management LLC acquired a new position in Eli Lilly and Company during the 1st quarter valued at about $54,000. Argentarii LLC increased its position in Eli Lilly and Company by 1.2% during the 1st quarter. Argentarii LLC now owns 4,744 shares of the company's stock valued at $3,918,000 after buying an additional 54 shares in the last quarter. McGlone Suttner Wealth Management Inc. increased its position in Eli Lilly and Company by 37.0% during the 1st quarter. McGlone Suttner Wealth Management Inc. now owns 1,052 shares of the company's stock valued at $869,000 after buying an additional 284 shares in the last quarter. Finally, Lee Danner & Bass Inc. increased its position in Eli Lilly and Company by 4.7% during the 1st quarter. Lee Danner & Bass Inc. now owns 585 shares of the company's stock valued at $483,000 after buying an additional 26 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on LLY shares. Hsbc Global Res lowered Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday, April 28th. Wells Fargo & Company reissued an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Guggenheim reaffirmed a "buy" rating and set a $936.00 target price on shares of Eli Lilly and Company in a report on Friday, June 20th. Morgan Stanley reiterated an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Finally, UBS Group cut their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. One analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $1,011.61.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY traded up $5.05 during midday trading on Tuesday, reaching $777.92. 3,299,275 shares of the company's stock traded hands, compared to its average volume of 3,667,370. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The company has a market cap of $737.26 billion, a P/E ratio of 63.30, a PEG ratio of 1.14 and a beta of 0.40. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37. The company has a fifty day simple moving average of $771.52 and a two-hundred day simple moving average of $800.30.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The company had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. During the same period last year, the business earned $2.58 earnings per share. The firm's revenue was up 45.2% compared to the same quarter last year. Equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.77%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's payout ratio is 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.